Rapamycin for the treatment of lymphangioleiomyomatosis
AssigneeAl Therapeutics, Inc.
InventorsHenri Lichenstein, Jonathan M. Rothberg, Thomas Armer, Lawrence S. Melvin, JR.
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods and compositions for treating lymphangioleiomyomatosis in a human subject in need of such treatment. The methods comprise administering to the subject via inhalation an aerosol composition comprising rapamycin or a prodrug or derivative (including analog) thereof.
Claims13
-49. (canceled)
A method for treating a lung disease or disorder characterized by aberrant activation of the mammalian target of rapamycin (mTOR) signaling pathway in a subject in need thereof, the method comprising administering to the subject by inhalation a pharmaceutical dry powder composition comprising microparticulate rapamycin and a carrier, wherein the microparticulate rapamycin consists of particles having a mass median aerodynamic diameter (MMAD) of from 2 to 3 microns, the microparticulate rapamycin is the only therapeutic agent in the composition, and the composition does not contain a surfactant or other additive.
Dependencies are inferred from the claim text.